

Canada's PharmAla Biotech incorporates Australian entity for clinical research

08 September 2025 | News

PharmAla Australia will receive a full and perpetual license to the company's ALA-002 asset and all associated patents



Canada based PharmAla Biotech Holdings Inc., a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), has incorporated PharmAla Biotech Australia Pty Ltd. ("PharmAla Australia"), a wholly-owned Australian subsidiary, for the purposes of conducting research and development activities in Australia.

PharmAla Australia will receive a full and perpetual license to the company's ALA-002 asset and all associated patents, and will be positioned to execute both manufacturing development and clinical research in Australia.

As many know, Australia continues to be a thriving market for biotech development. We believe that our familiarity with the market – our relationships and our experience - will drive significant synergies," said Nick Kadysh, Founding CEO, PharmAla Biotech.

PharmAla has appointed Dr Evan Lewis (MD, FRCPC, CSCN EEG Diplomate, CMLE, C-CAT (P)) to its Scientific Advisory Board, effective September 1, 2025.

Dr Evan Cole Lewis is an adult and pediatric neurologist with specialised training in epilepsy and pediatric neurology. His clinical focus includes epilepsy, brain injury, concussion and persistent post-concussion symptoms, functional neurological disorders—especially functional seizures—and the use of cannabis and psychedelics in neurological treatment.